Table 1.
Baseline characteristics of HCC patients with BDTT before and after PSM.
| Clinical variables | Before PSM | After PSM | ||||
|---|---|---|---|---|---|---|
| LR group (n = 105) | TACE group (n = 40) | P | LR group (n = 53) | TACE group (n = 28) | P | |
| Age, years | 54 (47–62) | 55 (45–62) | 0.827 | 50 (47–60) | 55 (45–62) | 0.676 |
| Sex | 0.548 | 0.758 | ||||
| Male | 86 (81.9%) | 31 (77.5%) | 45 (84.9%) | 23 (82.1%) | ||
| Female | 19 (18.1%) | 9 (22.5%) | 8 (15.1%) | 5 (17.9%) | ||
| Child–Pugh class | 0.266 | 0.252 | ||||
| A | 63 (60.0%) | 28 (70.0%) | 29 (54.7%) | 19 (67.9%) | ||
| B | 42 (40.0%) | 12 (30.0%) | 24 (45.3%) | 9 (32.1%) | ||
| HBsAg | 0.049 | 0.622 | ||||
| Positive | 63 (60.0%) | 31 (77.5%) | 37 (69.8%) | 21 (75.0%) | ||
| Negative | 42 (40.0%) | 9 (22.5%) | 16 (30.2%) | 7 (25.0%) | ||
| HBeAg | 0.014 | 1.000 | ||||
| Positive | 7 (6.7%) | 9 (22.5%) | 7 (13.2%) | 3 (10.7%) | ||
| Negative | 98 (93.3%) | 31 (77.5%) | 46 (86.8%) | 25 (89.3%) | ||
| Anti-HCV | 0.305 | 1.000 | ||||
| Positive | 2 (1.9%) | 2 (5.0%) | 1 (1.9%) | 1 (3.6%) | ||
| Negative | 103 (98.1%) | 38 (95.0%) | 52 (98.1%) | 27 (96.4%) | ||
| HBV DNA, copies/ml | 0.155 | 0.836 | ||||
| ≤1,000 | 85 (81.0%) | 28 (70.0%) | 39 (73.6%) | 20 (71.4%) | ||
| >1,000 | 20 (19.0%) | 12 (30.0%) | 14 (26.4%) | 8 (28.6%) | ||
| WBC, 109/L | 5.4 (4.4–7.4) | 5.2 (3.8–7.2) | 0.320 | 5.9 (4.5–7.4) | 5.2 (3.8–7.8) | 0.421 |
| HGB, g/L | 129 (16) | 125 (18) | 0.165 | 129 (18) | 125 (18) | 0.368 |
| PLT, 109/L | 180 (142–276) | 169 (120–220) | 0.125 | 173 (140–302) | 185 (121–256) | 0.545 |
| ALB, g/L | 39.6 (37.0–42.2) | 37.1 (34.6–41.0) | 0.040 | 39.0 (36.4–42.3) | 37.2 (34.5–40.4) | 0.113 |
| TBIL, umol/L | 21.4 (13.3–117.5) | 27.3 (19.7–44.1) | 0.676 | 31.5 (14.4–161.3) | 28.6 (21.8-44.1) | 0.659 |
| ALT, U/L | 62.8 (31.5–104.0) | 50.5 (29.8–104.8) | 0.580 | 64.0 (41.5–105.5) | 50.5 (33.3–101.2) | 0.379 |
| GGT, U/L | 313.0 (193.0–587.0) | 324.0 (188.3–523.3) | 0.963 | 307.0 (205.5–562.5) | 343.0 (210.8–554.0) | 0.743 |
| ALP, U/L | 189.0 (116.5–307.5) | 179.5 (133.5–269.5) | 0.907 | 189.0 (126.0–321.5) | 169.0 (125.8–269.5) | 0.487 |
| PT, s | 11.7 (11.2–12.4) | 12.3 (11.5–13.8) | 0.002 | 12.2 (11.5–13.0) | 12.3 (11.3–13.5) | 0.350 |
| Scr, umol/L | 65.5 (12.2) | 65.3 (14.1) | 0.927 | 65.8 (13.1) | 68.4 (15.0) | 0.415 |
| CA 19-9, U/ml | 56.3 (19.6–190.2) | 71.5 (29.9–145.2) | 0.540 | 78.5 (26.6–177.8) | 71.5 (27.7–138.9) | 0.800 |
| AFP, ng/ml | 0.186 | 0.114 | ||||
| ≤400 | 75 (71.4%) | 24 (60.0%) | 36 (67.9%) | 14 (50.0%) | ||
| >400 | 30 (28.6%) | 16 (40.0%) | 17 (32.1%) | 14 (50.0%) | ||
| Tumor diameter, cm | 0.071 | 0.976 | ||||
| ≤5 | 57 (54.3%) | 15 (37.5%) | 21 (39.6%) | 11 (39.3%) | ||
| >5 | 48 (45.7%) | 25 (62.5%) | 32 (60.4%) | 17 (60.7%) | ||
| Tumor number | 0.030 | 0.612 | ||||
| Solitary | 86 (81.9%) | 26 (65.0%) | 37 (69.8%) | 18 (64.3%) | ||
| Multiple | 19 (18.1%) | 14 (35.0%) | 16 (30.2%) | 10 (35.7%) | ||
| Macrovascular invasion | <0.001 | 0.688 | ||||
| Presence | 4 (3.8%) | 10 (25.0%) | 4 (7.5%) | 3 (10.7%) | ||
| Absence | 101 (96.2%) | 30 (75.0%) | 49 (92.5%) | 25 (89.3%) | ||
HCC, hepatocellular carcinoma; BDTT, bile duct tumor thrombus; PA-TACE, postoperative adjuvant transarterial chemoembolization; LR, liver resection; HBsAg, hepatitis-B antigen; ALB, albumin; ALT, alanine aminotransferase; TBil, total bilirubin; PT, prothrombin time; AFP, alpha-fetoprotein; EBDR, extrahepatic bile duct resection; PVTT, portal vein tumor thrombus.
Statistically significant values are depicted as bold format.